Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen

World Journal of Surgical Oncology

Vesna Bišof²  Ana Mišir Krpan²  Luka Simetić²  David Ozretić¹  Zoran Rakušić²  Natalija Dedić Plavetić² 

[1] Department of Radiology, University Hospital Center, Kišpatićeva 12, HR-10 000 Zagreb, Croatia;Department of Oncology, University Hospital Center, Kišpatićeva 12, HR-10000 Zagreb, Croatia

关键词: Posterior reversible encephalopathy syndrome;    Irinotecan;    Fluorouracil;    Fluoropyrimidine;    Chemotherapy;   

Others  :  1148285
DOI  :  10.1186/1477-7819-12-264

 received in 2014-06-18, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity characterized by headaches, altered mental status, seizures, and visual disturbances. It can occur in many different clinical entities such as severe hypertension and pre-eclampsia, or due to cytotoxic or immunosuppressive therapies. The pathogenesis of PRES is unclear, with dysregulated cerebral auto-regulation and endothelial dysfunction as important mechanisms proposed. Endothelial dysfunction is important especially in cases associated with cytotoxic therapies. Herein, we describe a patient with PRES with fatal outcome, who presented 5 days after the infusion of cycle 1 of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy, without prior hypertension and other comorbidity, suggesting a link between PRES and FOLFIRI regimen. To our knowledge, this case report is the first describing PRES after FOLFIRI regimen, although others have described PRES after FOLFIRI with bevacizumab in colonic cancer patients.

【 授权许可】

   
2014 Dedić Plavetić et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA: Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010, 85:427-432.
• [2]Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494-500.
• [3]Bathla G, Hegde AN: MRI and CT appearances in metabolic encephalopathies due to systemic diseases in adults. Clin Radiol 2013, 68:545-554.
• [4]Garg RK: Posterior leukoencephalopathy syndrome. Postgrad Med J 2001, 77:24-28.
• [5]Bartynski WS: Posterior reversible encephalopathy syndrome. Part 2. Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008, 29:1043-1049.
• [6]Bartynski WS, Boardman JF: Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. Am J Neuroradiol 2008, 29:447-455.
• [7]Covarrubias DJ, Luetmer PH, Campeau NG: Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. Am J Neuroradiol 2002, 23:1038.
• [8]Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475.
• [9]Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354(9):980-982.
• [10]Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982.
• [11]Sclafani F, Gullo G, Mezynksi J, Collins C, Crown J: Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol 2012, 30(26):e257-e259.
• [12]Kidwell CS, Ager JR, Di Salle F, Starkman S, Villablanca P, Bentson J, Saver JL: Diffusion MRI in patients with transient ischemic attacks. Stroke 1999, 30:1174-1180.
• [13]Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM: Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004, 77:72-76.
• [14]Femia G, Hardy TA, Spies JM, Horvath LG: Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pac J Clin Oncol 2012, 8:115-122.
• [15]Posner JB: Neurotoxicity of 5-fluorouracil and levamisole. Neurol Network Commentary 1997, 1:239-243.
• [16]Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG, Rodriguez M: Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992, 31:262-267.
• [17]Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
• [18]Norman JK, Parke JT, Wilson DA, McNall-Knapp RY: Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007, 49(2):198-203.
• [19]Bartynski WS, Boardman JF: Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol 2007, 28:1320-1327.
• [20]Hugonnet E, Da Ines D, Boby H, Claise B, Petitcolin V, Lannareixa V, Garciera JM: Posterior reversible encephalopathy syndrome (PRES): Features on CT and MR imaging. Diagn Interv Imaging 2013, 94:45-52.
• [21]Stevens CJ, Heran MKS: The many faces of posterior reversible encephalopathy syndrome. Br J Radiol 2012, 85:1566-1575.
• [22]Bartynski WS: Posterior reversible encephalopathy syndrome. Part 1. Fundamental imaging and clinical features. Am J Neuroradiol 2008, 29:1036-1042.
• [23]Hefzy HM, Bartynski WS, Boardman JF, Lacomis D: Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. Am J Neuroradiol 2009, 30:1371-1379.